US Patent 11447521 Compounds and methods for modulating angiotensinogen expression
Patent 11447521 was granted and assigned to Ionis Pharmaceuticals on September, 2022 by the United States Patent and Trademark Office.
All edits
US Patent 11447521 Compounds and methods for modulating angiotensinogen expression
Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of AGT RNA in a cell or subject, and in certain instances reducing the amount of AGT in a cell or subject. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a cardiovascular disease. Such compound and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a RAAS pathway-related disease or disorder. Such symptoms and hallmarks include hypertension, chronic kidney disease, stroke, myocardial infarction, heart failure, valvular heart disease, aneurysms of the blood vessels, peripheral artery disease, and organ damage. Such cardiovascular diseases include hypertension, resistant hypertension, Marfan syndrome, and heart failure.
Find more entities like US Patent 11447521 Compounds and methods for modulating angiotensinogen expression
